Ditchcarbon
  • Customers
  1. Organizations
  2. Indivior
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 2 months ago

Indivior

Company website

Indivior PLC, a global leader in addiction treatment, is headquartered in the United States and operates extensively across North America and Europe. Founded in 2014, the company has rapidly established itself within the pharmaceutical industry, focusing on innovative solutions for opioid dependence and other substance use disorders. Indivior is renowned for its flagship product, Suboxone, which combines buprenorphine and naloxone to effectively manage opioid addiction while minimising misuse potential. This unique formulation has positioned Indivior as a key player in the market, contributing to significant advancements in addiction therapy. With a commitment to improving patient outcomes, Indivior has achieved notable milestones, including regulatory approvals and partnerships that enhance its service offerings. The company continues to lead the way in addressing the global opioid crisis, solidifying its reputation as a trusted provider in the addiction treatment sector.

DitchCarbon Score

How does Indivior's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

46

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

29

Industry Benchmark

Indivior's score of 46 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.

68%

Let us know if this data was useful to you

Indivior's reported carbon emissions

In 2024, Indivior reported total carbon emissions of approximately 4,102,000 kg CO2e, with emissions distributed across various scopes: 289,000 kg CO2e from Scope 1, 368,000 kg CO2e from Scope 2 (market-based), and a significant 3,445,000 kg CO2e from Scope 3. This represents a notable decrease from 2023, where total emissions were about 6,126,000 kg CO2e, comprising 405,000 kg CO2e (Scope 1), 701,000 kg CO2e (Scope 2, market-based), and 5,020,000 kg CO2e (Scope 3). Indivior has set ambitious climate commitments, aiming for a 100% transition to hybrid vehicles by the end of 2026, which applies to both Scope 1 and Scope 2 emissions. Additionally, the company is optimistic about achieving net-zero emissions by 2050, contingent on a globally coordinated effort towards decarbonisation. The emissions data is sourced directly from Indivior PLC, with no cascading from a parent organisation. Indivior's commitment to reducing its carbon footprint aligns with industry standards and reflects a proactive approach to climate change mitigation.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

201920202021202220232024
Scope 1
699,000
000,000
0,000,000
0,000,000
0,000,000
0,000,000
Scope 2
2,592,000
0,000,000
0,000,000
0,000,000
0,000,000
0,000,000
Scope 3
140,000
000,000
-
-
000,000,000
000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Indivior's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Indivior is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Indivior is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Sandoz International GmbH

DE
•
Pharmaceutical Preparation Manufacturing
Updated 30 days ago

Otsuka Pharmaceutical Co., Ltd.

JP
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Bristol-Myers Squibb

US
•
Pharmaceutical Preparation Manufacturing
Updated about 13 hours ago

Vectura

GB
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Novartis

CH
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

RECORDATI

LU
•
Pharmaceutical Preparation Manufacturing
Updated about 1 hour ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
dev
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy